In Vivo CAR-T (U96) cell therapy (The First Affiliated Hospital of Soochow University)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameIn Vivo CAR-T (U96) cell therapy (The First Affiliated Hospital of Soochow University)
Drug Alias NameCD7-targeted lentiviral vector for in vivo production of IL-6 knockdown CD19 CAR T cell therapy (The First Affiliated Hospital of Soochow University)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD7
TargetsT-cell antigen CD7
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe First Affiliated Hospital Of Soochow University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Soochow University
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A